Double disruption of α2A- and α2C-adrenoceptors induces endothelial dysfunction in mouse small arteries: Role of nitric oxide synthase uncoupling

Experimental Physiology

Volumn 99, Issue 10, 2014, Pages 1427-1438

  Couto, Gisele K ^a   Davel, Ana P ^b   Brum, Patrícia C ^a   Rossoni, Luciana V ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

4,5 DIAMINOFLUORESCEIN DIACETATE; ALPHA 2A ADRENERGIC RECEPTOR; ALPHA 2C ADRENERGIC RECEPTOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ETHIDIUM BROMIDE; N(G) NITROARGININE METHYL ESTER; NORADRENALIN; SEROTONIN; SUPEROXIDE; ALPHA 2 ADRENERGIC RECEPTOR; ENZYME INHIBITOR;

ANIMAL EXPERIMENT; AORTA; ARTERY; ARTERY CONSTRICTION; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DIMERIZATION; ENDOTHELIAL DYSFUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART RATE; HEART VENTRICLE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; MESENTERIC ARTERY; METABOLISM; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ANIMALS; AORTA; BLOOD PRESSURE; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HEART RATE; MALE; MESENTERIC ARTERIES; MICE; MICE, KNOCKOUT; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE TYPE III; RECEPTORS, ADRENERGIC, ALPHA-2;

EID: 84908365224     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2014.079236     Document Type: Article

References (54)

1. 2A-adrenergic receptor knockout mice. Mol Pharmacol 56, 154-161.
2. Alvarez Y, Briones AM, Hernanz R, Pérez-Girón JV, Alonso MJ & Salaices M (2008). Role of NADPH oxidase and iNOS in vasoconstrictor responses of vessels from hypertensive and normotensive rats. Br J Pharmacol 153, 926-935.
3. Alves MJ, Rondon MU, Santos AC, Dias RG, Barretto AC, Krieger EM, Middlekauff HR & Negrão CE (2007). Sympathetic nerve activity restrains reflex vasodilatation in heart failure. Clin Auton Res 17, 364-369.
4. Arimura K, Egashira K, Nakamura R, Ide T, Tsutsui H, Shimokawa H & Takeshita A (2001). Increased inactivation of nitric oxide is involved in coronary endothelial dysfunction in heart failure. Am J Physiol Heart Circ Physiol 280, H68-H75.
5. Bauersachs J, Bouloumié A, Fraccarollo D, Hu K, Busse R & Ertl G (1999). Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: role of enhanced vascular superoxide production. Circulation 100, 292-298.
6. Bendall JK, Alp NJ, Warrick N, Cai S, Adlam D, Rockett K, Yokoyama M, Kawashima S & Channon KM (2005). Stoichiometric relationships between endothelial tetrahydrobiopterin, endothelial NO synthase (eNOS) activity, and eNOS coupling in vivo: insights from transgenic mice with endothelial-targeted GTP cyclohydrolase 1 and eNOS overexpression. Circ Res 97, 864-871.
7. Bitar MS, Wahid S, Mustafa S, Al-Saleh E, Dhaunsi GS & Al-Mulla F (2005). Nitric oxide dynamics and endothelial dysfunction in type II model of genetic diabetes. Eur J Pharmacol 511, 53-64.
8. Bouloumié A, Bauersachs J, Linz W, Schölkens BA, Wiemer G, Fleming I & Busse R (1997). Endothelial dysfunction coincides with an enhanced nitric oxide synthase expression and superoxide anion production. Hypertension 30, 934-941.
9. Brum PC, Kosek J, Patterson A, Bernstein D & Kobilka B (2002). Abnormal cardiac function associated with sympathetic nervous system hyperactivity in mice. Am J Physiol Heart Circ Physiol 283, H1838-H1845.
10. Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP, Molinoff PB, Ruffolo RR & Trendelenburg AU (1994). International union of pharmacology nomenclature of adrenoceptors. Pharmacol Rev 46, 121-136.
11. Cai S, Khoo J, Mussa S, Alp NJ & Channon KM (2005). Endothelial nitric oxide synthase dysfunction in diabetic mice: importance of tetrahydrobiopterin in eNOS dimerisation. Diabetologia 48, 1933-1940.
12. Channon KM (2004). Tetrahydrobiopterin: regulator of endothelial nitric oxide synthase in vascular disease. Trends Cardiovasc Med 14, 323-327.
13. Chen Y, Hou M, Li Y, Traverse JH, Zhang P, Salvemini D, Fukai T & Bache RJ (2005). Increased superoxide production causes coronary endothelial dysfunction and depressed oxygen consumption in the failing heart. Am J Physiol Heart Circ Physiol 288, H133-H141.
14. 2-adrenoceptors in human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 286, H59-H67.
15. 2-adrenoceptor signaling pathway. PLoS ONE 9, e91877.
16. 2-adrenoceptor knockout mice: the role of NADPH oxidase. J Vasc Res 49, 342-352.
17. Davel AP, Fukuda LE, De Sá LL, Munhoz CD, Scavone C, Sanz-Rosa D, Cachofeiro V, Lahera V & Rossoni LV (2008). Effects of isoproterenol treatment for 7 days on inflammatory mediators in the rat aorta. Am J Physiol Heart Circ Physiol 295, H211-H219.
18. Davel AP, Kawamoto EM, Scavone C, Vassallo DV & Rossoni LV (2006). Changes in vascular reactivity following administration of isoproterenol for 1 week: a role for endothelial modulation. Br J Pharmacol 148, 629-639.
19. Dinenno FA, Dietz NM & Joyner MJ (2002). Aging and forearm postjunctional α-adrenergic vasoconstriction in healthy men. Circulation 106, 1349-1354.
20. Eisenach JH, Clark ES, Charkoudian N, Dinenno FA, Atkinson JL, Fealey RD, Dietz NM & Joyner MJ (2002). Effects of chronic sympathectomy on vascular function in the human forearm. J Appl Physiol 92, 2019-2025.
21. Ferreira JCB, Bacurau AV, Evangelista FS, Coelho MA, Oliveira EM, Casarini DE, Krieger JE & Brum PC (2008). The role of local and systemic rennin angiotensin system activation in a genetic model of sympathetic hyperactivity-induced heart failure in mice. Am J Physiol Regul Integr Comp Physiol 294, R26-R32.
22. 2-adrenoceptor activation. Br J Pharmacol 134, 957-968.
23. Flavahan NA (2005). Phenylpropanolamine constricts mouse and human blood vessels by preferentially activating α2-adrenoceptors. J Pharmacol Exp Ther 313, 432-439.
24. Förstermann U (2010). Nitric oxide and oxidative stress in vascular disease. Pflugers Arch 459, 923-939.
25. 2-adrenergic receptor subtypes. Nature 402, 181-184.
26. Katz SD, Khan T, Zeballos GA, Mathew L, Potharlanka P, Knecht M & Whelan J (1999). Decreased activity of the l-arginine-nitric oxide metabolic pathway in patients with congestive heart failure. Circulation 99, 2113-2117.
27. Ketonen J, Pilvi T & Mervaala E (2010). Caloric restriction reverses high-fat diet-induced endothelial dysfunction and vascular superoxide production in C57Bl/6 mice. Heart Vessels 25, 254-262.
28. Konishi M & Su C (1983). Role of endothelium in dilator responses of spontaneously hypertensive rat arteries. Hypertension 5, 881-886.
29. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE & Harrison DG (2003). Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 111, 1201-1209.
30. Lobato NS, Filgueira FP, Akamine EH, Davel AP, Rossoni LV, Tostes RC, Carvalho MH & Fortes ZB (2011). Obesity induced by neonatal treatment with monosodium glutamate impairs microvascular reactivity in adult rats: role of NO and prostanoids. Nutr Metab Cardiovasc Dis 21, 808-816.
31. 2A-adrenergic receptor subtype. Science 273, 801-803.
32. Medeiros A, Rolim NP, Oliveira RS, Rosa KT, Mattos KC, Casarini DE, Irigoyen MC, Krieger EM, Krieger JE, Negrão CE & Brum PC (2008). Exercise training delays cardiac dysfunction and prevents calcium handling abnormalities in sympathetic hyperactivity-induced heart failure mice. J Appl Physiol 104, 103-109.
33. Molin JC & Bendhack LM (2004). Clonidine induces rat aorta relaxation by nitric oxide-dependent and -independent mechanisms. Vascul Pharmacol 42, 1-6.
34. Mulvany MJ & Halpern W (1977). Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 41, 19-26.
35. Oliveira RSF, Ferreira JCB, Gomes ERM, Paixão NA, Rolim NPL, Medeiros A, Guatimosim S & Brum PC (2009). Cardiac anti-remodelling effect of aerobic training is associated with a reduction in the calcineurin/NFAT signalling pathway in heart failure mice. J Physiol 587, 3899-3910.
36. Panza JA, Casino PR, Kilcoyne CM & Quyyumi AA (1993). Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 87, 1468-1474.
37. Pereira RB, Sartório CL, Vassallo DV & Stefanon I (2005). Differences in tail vascular bed reactivity in rats with and without heart failure following myocardial infarction. J Pharmacol Exp Ther 312, 1321-1325.
38. Pérez-Rivera AA, Hlavacova A, Rosario-Colón LA, Fink GD & Galligan JJ (2007). Differential contributions of alpha-1 and alpha-2 adrenoceptors to vasoconstriction in mesenteric arteries and veins of normal and hypertensive mice. Vascul Pharmacol 46, 373-382.
39. Pfeffer MA & Braunwald E (1990). Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 81, 1161-1172.
40. Phillips JK, Vidovic M & Hill CE (1997). Variation in mRNA expression of alpha-adrenergic, neurokinin and muscarinic receptors amongst four arteries of the rat. J Auton Nerv Syst 62, 85-93.
41. 2+ handling protein expression in heart failure. Physiol Genomics 29, 246-252.
42. Russell A & Watts S (2000). Vascular reactivity of isolated thoracic aorta of the C57BL/6J mouse. J Pharmacol Exp Ther 294, 598-604.
43. Santos AC, Alves MJ, Rondon MU, Barretto AC, Middlekauff HR & Negrão CE (2005). Sympathetic activation restrains endothelium-mediated muscle vasodilatation in heart failure patients. Am J Physiol Heart Circ Physiol 289, H593-H599.
44. Sartório CL, Fraccarollo D, Galuppo P, Leutke M, Ertl G, Stefanon I & Bauersachs J (2007). Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction. Hypertension 50, 919-925.
45. Shi AG, Kwan CY & Daniel EE (1989). Relation between density (maximum binding) of alpha adrenoceptor binding sites and contractile response in four canine vascular tissues. J Pharmacol Exp Ther 250, 1119-1124.
46. 2-adrenoreceptors contributes to enhanced constrictor effects of norepinephrine in mesenteric veins compared to arteries. Eur J Pharmacol 643, 239-246.
47. Stassen FRM, Maas RGHT, Schiffers PMH, Janssen GMT & de Mey JGR (1998). A positive and reversible relationship between adrenergic nerves and alpha-1A adrenoceptors in rat arteries. J Pharmacol Exp Ther 284, 399-405.
48. Taddei S, Virdis A, Mattei P & Salvetti A (1993). Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 21, 929-933.
49. Teerlink JR, Gray GA, Clozel M & Clozel JP (1994). Increased vascular responsiveness to norepinephrine in rats with heart failure is endothelium dependent. Dissociation of basal and stimulated nitric oxide release. Circulation 89, 393-401.
50. 2-adrenoceptor-mediated endothelium-dependent vasodilation. Circ Res 82, 1323-1329.
51. Varin R, Mulder P, Richard V, Tamion F, Devaux C, Henry JP, Lallemand F, Lerebours G & Thuillez C (1999). Exercise improves flow-mediated vasodilatation of skeletal muscle arteries in rats with chronic heart failure. Role of nitric oxide, prostanoids, and oxidant stress. Circulation 99, 2951-2957.
52. Wang Y, Wang S, Wier WG, Zhang Q, Jiang H, Li Q, Chen S, Tian Z, Li Y, Yu X, Zhao M, Liu J, Yang J, Zhang J & Zang W (2010). Exercise improves the dilatation function of mesenteric arteries in postmyocardial infarction rats via a PI3K/Akt/eNOS pathway-mediated mechanism. Am J Physiol Heart Circ Physiol 299, H2097-H2106.
53. Zalba G, Beaumont FJ, San José G, Fortuño A, Fortuño MA, Etayo JC & Díez J (2000). Vascular NADH/NADPH oxidase is involved in enhanced superoxide production in spontaneously hypertensive rats. Hypertension 35, 1055-1061.
54. 2-adrenoceptor activation. J Appl Physiol 82, 1918-1925.